I. Idris

First name
I.
Last name
Idris
Idris, I., Zhang, R., Mamza, J. B., Ford, M., Morris, T., Banerjee, A., & Khunti, K. (2022). Significant reduction in chronic kidney disease progression with sodium-glucose cotransporter-2 inhibitors compared to dipeptidyl peptidase-4 inhibitors in adults with type 2 diabetes in a UK clinical setting. Diabetes Obes Metab. http://doi.org/10.1111/dom.14799
Gordon, J., McEwan, P., Idris, I., Evans, M., & Puelles, J. (2018). Treatment choice, medication adherence and glycemic efficacy in people with type 2 diabetes: a UK clinical practice database study. BMJ Open Diabetes Res Care. http://doi.org/10.1136/bmjdrc-2018-000512
Idris, I., Peng, X., He, X., Liu, D., Balogh, E., Kaushik, P., & van Brunt, K. (2018). The Trend of High-Dose Insulin Usage Among Patients with Diabetes in the UK: A Retrospective Study. Diabetes Ther. http://doi.org/10.1007/s13300-018-0515-0
Webb, J., Mount, J., von Arx, L. B., Rachman, J., Spanopoulos, D., Wood, R., et al. (2021). Cardiovascular risk profiles: A cross-sectional study evaluating the generalisability of the glucagon-like peptide-1 receptor agonist cardiovascular outcome trials Rewind, Leader and Sustain-6 to the real-world type 2 diabetes population in the UK. Diabetes Obes Metab. http://doi.org/10.1111/dom.14580